- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Potential Research Study Participant Registry (clinicaltrials.gov) - Feb 16, 2019
P=N/A, N=265, Completed, Phase classification: P2a --> P2 Recruiting --> Completed | N=200 --> 265 | Trial completion date: Jan 2025 --> Sep 2018 | Trial primary completion date: Jan 2025 --> Sep 2018
- |||||||||| Sorilux (calcipotriene foam) / Mayne Pharma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis (clinicaltrials.gov) - Jan 22, 2019 P1, N=36, Completed, Recruiting --> Completed | N=200 --> 265 | Trial completion date: Jan 2025 --> Sep 2018 | Trial primary completion date: Jan 2025 --> Sep 2018 Recruiting --> Completed | N=75 --> 36 | Trial completion date: Apr 2019 --> Aug 2018 | Trial primary completion date: Apr 2019 --> Aug 2018
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date, IO biomarker: Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques (clinicaltrials.gov) - Jan 5, 2019
P2, N=7, Completed, Recruiting --> Completed | N=75 --> 36 | Trial completion date: Apr 2019 --> Aug 2018 | Trial primary completion date: Apr 2019 --> Aug 2018 Recruiting --> Completed | N=10 --> 7 | Trial completion date: Jul 2017 --> Feb 2018 | Trial primary completion date: Jul 2017 --> Mar 2017
- |||||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion, Trial completion date, Trial primary completion date: Initial Treatment With Golimumab in Early PsA (clinicaltrials.gov) - Nov 26, 2018 P3, N=51, Completed, Completed --> Terminated Recruiting --> Completed | Trial completion date: Dec 2016 --> Nov 2018 | Trial primary completion date: Jun 2016 --> Nov 2018
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen, Yisaipu (etanercept biosimilar) / Cipla, 3SBio, Abbott
Trial completion, Trial primary completion date: Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate (clinicaltrials.gov) - Aug 17, 2018 P4, N=466, Completed, Recruiting --> Completed | Trial completion date: Dec 2016 --> Nov 2018 | Trial primary completion date: Jun 2016 --> Nov 2018 Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Aug 2018
- |||||||||| Trial completion, Phase classification, Trial completion date: Natural Gels for Treatment of Plaque Psoriasis (clinicaltrials.gov) - Jul 23, 2018
P2/3, N=45, Completed, Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Aug 2018 Recruiting --> Completed | Phase classification: P1/2 --> P2/3 | Trial completion date: Dec 2016 --> Sep 2017
- |||||||||| Stelara (ustekinumab) / J&J
Trial completion, Reimbursement, Trial completion date, Trial primary completion date, Claims database: Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database (clinicaltrials.gov) - Jun 15, 2018 P=N/A, N=2000, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Sep 2017 | Trial primary completion date: Apr 2018 --> Sep 2017
- |||||||||| Humira (adalimumab) / AbbVie
Trial completion: Vascular Inflammation in Psoriasis Trial (The VIP Trial) (clinicaltrials.gov) - Jun 3, 2018 P4, N=97, Completed, Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Sep 2017 | Trial primary completion date: Apr 2018 --> Sep 2017 Active, not recruiting --> Completed
- |||||||||| tacrolimus topical / Generic mfg.
Trial completion, Enrollment change, Trial completion date: Tacrolimus Ointment Interest (PROTOPIC (clinicaltrials.gov) - Jun 1, 2018 P3, N=120, Completed, Active, not recruiting --> Completed Recruiting --> Completed | N=240 --> 120 | Trial completion date: Jun 2018 --> Oct 2017
- |||||||||| Phase classification, Enrollment change: Genetic Analysis of Psoriasis and Psoriatic Arthritis (clinicaltrials.gov) - Apr 6, 2018
P, N=2653, Completed, Recruiting --> Completed | N=240 --> 120 | Trial completion date: Jun 2018 --> Oct 2017 Phase classification: P=N/A --> P | N=5000 --> 2653
- |||||||||| calcipotriol/betamethasone dipropionate / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects (clinicaltrials.gov) - Mar 1, 2018 P2, N=102, Completed, Trial completion date: Jan 2018 --> Mar 2018 | Initiation date: Apr 2014 --> Feb 2010 | Trial primary completion date: Jan 2018 --> Mar 2018 Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Feb 2018 | Trial completion date: Dec 2017 --> Feb 2018
- |||||||||| Cosentyx (secukinumab) / Novartis
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date: 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis (clinicaltrials.gov) - Feb 28, 2018 P3, N=675, Completed, Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Feb 2018 | Trial completion date: Dec 2017 --> Feb 2018 Active, not recruiting --> Completed | Initiation date: Sep 2012 --> Aug 2008 | Trial completion date: May 2017 --> May 2017 | Trial primary completion date: May 2017 --> May 2017
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Oct 19, 2017 P=N/A, N=96, Completed, N=15 --> 10 Active, not recruiting --> Completed | N=140 --> 96
- |||||||||| Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Trial completion, HEOR: Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation (clinicaltrials.gov) - Oct 13, 2017 P=N/A, N=26, Completed, Active, not recruiting --> Completed | N=140 --> 96 Active, not recruiting --> Completed
- |||||||||| Trial completion: The NOR-SWITCH Study (clinicaltrials.gov) - Sep 25, 2017
P4, N=482, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion, Review, Trial primary completion date: Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis (clinicaltrials.gov) - Sep 6, 2017 P=N/A, N=370, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2016
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, IO biomarker: Mechanism of Action Study for Psoriasis (clinicaltrials.gov) - Aug 31, 2017 P4, N=33, Completed, Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2016 Active, not recruiting --> Completed
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Trial primary completion date: VIP-Et: Vascular Inflammation in Psoriasis - Extension Study (clinicaltrials.gov) - Jun 16, 2017 P4, N=81, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2018 --> Aug 2016
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Neurobiology of the Scalp in Seborrheic Dermatitis (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=32, Completed, Phase classification: P4 --> P=N/A Recruiting --> Completed | N=24 --> 32 | Trial primary completion date: Aug 2015 --> May 2014
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Trial primary completion date, Real-world evidence, Real-world: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (clinicaltrials.gov) - Mar 21, 2017 P3, N=46, Completed, Active, not recruiting --> Completed | N=150 --> 116 Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Mar 2017
- |||||||||| Trial completion, Enrollment change: Prevalence of Sleep Disturbances in Psoriasis (clinicaltrials.gov) - Mar 13, 2017
P=N/A, N=64, Completed, Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Mar 2017 Active, not recruiting --> Completed | N=80 --> 64
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Phase classification, Review: Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis (clinicaltrials.gov) - Mar 3, 2017 P=N/A, N=370, Active, not recruiting, N=128 --> 43 Phase classification: P4 --> P=N/A
|